Table 2.
Prevalence of acute and delayed nausea and vomiting
| Prevalence of treatment failures | Number (%) | P valuea | P valueb | ||
|---|---|---|---|---|---|
|
|
|||||
| Placebo group (n=46) | Ginger 1.0 g group (n=43) | Ginger 2.0 g group (n=40) | |||
| Nausea | |||||
| Acute | |||||
| No apripetant | 23 (50.0) | 21 (48.8) | 20 (50.0) | 0.76 | 0.86 |
| Yes apripetant | 8 (17.4) | 12 (27.9) | 10 (25.0) | ||
| Delayed | |||||
| No apripetant | 23 (50.0) | 26 (60.5) | 17 (42.5) | 0.15 | 0.16 |
| Yes apripetant | 8 (17.4) | 11 (25.6) | 10 (25.0) | ||
| Vomiting | |||||
| Acute | |||||
| No apripetant | 11 (23.9) | 14 (26.4) | 11 (27.5) | 0.35 | 0.47 |
| Yes apripetant | 3 (6.5) | 5 (11.6) | 6 (15.0) | ||
| Delayed | |||||
| No apripetant | 8 (52.6) | 14 (32.6) | 7 (17.5) | 0.35 | 0.07 |
| Yes apripetant | 1 (2.2) | 5 (11.6) | 5 (12.5) | ||
a
P values were calculated using Cochran Mantel-Haenszel tests stratified by apripetant (yes or no)
b
P values are Pearson chi-squares calculated using logistic regression adjusting for emetic risk of the chemotherapeutic agent (high, moderate, low), apripetant, presence or absence of baseline nausea or vomiting (yes or no) as appropriate for delayed values and presence or absence of acute nausea or vomiting (yes or no) as appropriate for acute measures